Newly announced findings from a Phase III trial conducted by CytoDyn indicate that the use of the late-stage biotechnology company’s CCR5 antagonist candidate Vyrologix (leronlimab) was safe and improved the survival rate in critically ill hospitalized patients with coronavirus disease 2019.
Mesenchymal stem cells derived from umbilical cord tissue could help treat ARDS in Covid-19 patients, according to results of a Phase I/IIa clinical trial published by University of Miami researchers.
Humanigen and EVERSANA Announce Partnership to Support Launch and Commercialization of Lenzilumab for Treatment of COVID-19
Biologics License Application (BLA), Business, Coronavirus Disease 2019 (COVID-19), Cytokine Storm, Emergency Use Authorization (EUA), Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), Hospitalized COVID-19 Patients, Partnerships, Product LaunchesHumanigen Inc. and EVERSANA announced that they are partnering to make lenzilumab available to hospitalized and hypoxic Covid-19 patients in the event that an Emergency Use Authorization is issued from the U.S. Food and Drug Administration and subsequent BLA.
BioSpace presented the NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
AstraZeneca and Amgen said their experimental asthma drug tezepelumab failed to meet the main goal of reducing patients’ dependence on steroids, while keeping the respiratory condition in check in a late-stage trial.
Incyte and Novartis announced a Phase III study of Jakafi (ruxolitinib), a first-in-class JAK1/JAK2 inhibitor, failed to hit endpoints as a treatment for patients 12 and up with Covid-19 associated cytokine storm.
Inflammation: A necessity and a threat to COVID-19 patients
Anti-Inflammatory, Antibodies, Biology, Coronavirus Disease (COVID-19) Pandemic, COVID-19 Vaccines, Cytokines, Fall/Autumn, Inflammation, Patient Outcomes, SARS-CoV-2 virus, Symptoms: Coronavirus Disease 2019 (COVID-19), Tumor Necrosis Factor (TNF), WinterBlocking TNF production could offer a more effective solution for the treatment of COVID-19.
MediciNova’s Ibudilast Reduces Retinal Thinning in MS Trial Subjects
Cancer Chemotherapy and Pharmacology, Chemotherapy-Induced Peripheral Neuropathy (CIPN), Clinical Data, Clinical Trials, Cytokines, Multiple Sclerosis, Multiple Sclerosis Journal, Peripheral Neuropathy, Progressive Multiple Sclerosis (MS), R&D, Small MoleculesMediciNova received positive Optical Coherence Tomography (OCT) results from the company’s SPRINT-MS Phase IIb trial of MN-166 (ibudilast) in multiple sclerosis subjects.
Novartis inked an exclusive worldwide license and collaboration deal with Australia-based Mesoblast to develop, commercialize and manufacture remestemcel-L for acute respiratory distress syndrome (ARDS), including when it is linked to Covid-19.
Bristol Myers Squibb’s experimental psoriasis drug deucravacitinib (BMS-986165) beat out Amgen’s Otezla (apremilast) in the POETYK PSO-1 Phase III clinical trial.